Tag: FIGHT-203

Home / FIGHT-203

Categories

Pemigatinib is approved for relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement

November 2022: Pemigatinib (Pemazyre, Incyte Corporation) has been licenced by the Food and Drug Administration for use in people with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) that hav...
fight-203

Scan the code